Panel to evaluate FDA pharmacogenomics paper
FDA will convene its Pharmaceutical Science and Clinical Pharmacology Advisory Committee March 18 to evaluate the agency's clinical pharmacogenomics concept paper. Industry is requesting that FDA clarify elements of the companion guidance, and the panel will discuss issues pertaining to collection of samples and applications of pharmacogenomics in clinical development (1"The Pink Sheet," Dec. 10, 2007, p. 18). The panel also will address qualitative clinical pharmacology. On March 19, the panel will discuss the renal impairment concept paper...
You may also be interested in...
Industry is pressing FDA to enhance the utility of its "companion guidance" on pharmacogenomic data submissions as the agency refines the draft document
3D-printing company Carbon and in vitro diagnostics maker Resolution Medical announced plans to manufacture more than one million 3D-printed nasal swabs per week to test for COVID-19. See what Resolution Medical’s president Shawn Patterson said about it here.
FDA warning to "Genesis II Church of Health and Healing " wasn't its first to the organization about promoting a chlorine dioxide formulation, "Miracle Mineral Solution," as an unapproved new drug. 'Infowars' host Alex Jones also was warned about bogus COVID-19 claims.